Back to Search
Start Over
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
- Source :
- GlobeNewswire. February 13, 2025
- Publication Year :
- 2025
-
Abstract
- FY 2024 total sales growth of 9.9% at CER[sup.1], or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare [...]
- Subjects :
- Mecasermin
Cabozantinib
Working capital
Lanreotide
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.827292686